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Abstract
Background: Inhibitors of dipeptidyl-peptidase IV are recommended as second-line therapy in type 2 diabetes (DT2),
but data, as a first-line treatment in everyday clinical practice are scarce. To address this issue we conducted a 12-month,
clinical study in an outpatient setting, using vildagliptin as the first-line treatment.
Methods: Ninety-one drug naïve patients with DT2 started with vildagliptin monotherapy (100 mg daily) for 4 months
and were scheduled to regular 4-monthly visits for 1 year. Patients received add-on treatment with metformin or
metformin and glimepiride according to their glycosylated hemoglobin (HbA1c) at each study-visit.
Results: HbA1c was significantly decreased with vildagliptin monotherapy from 8.16 % ± 1.60 to 7.52 % ± 1.60,
p < 0.001. Only 39 % of the patients achieved the target of HbA1c ≤ 7.0 % at the end of the 4th month.
Mean change in HbA1c was significantly correlated with baseline HbA1c values (r = −0.51, p < 0.001). At the
end of the study only 35 % of the patients remained on vildagliptin monotherapy while the rest required
add-on treatment with metformin or metformin and sulfonylurea.
Conclusions: Vildagliptin is well tolerated either as monotherapy or in combination but the majority of
patients require add-on therapy shortly after the beginning of treatment.
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Background
Drugs focusing on the incretin system, such as dipepti-
dyl peptidase 4 inhibitors (DPP-4i) and glucagon–like
peptide −1 (GLP-1) analogues have been recently intro-
duced in the clinical practice for the treatment of dia-
betes type 2 demonstrating efficacy and a favorable
safety profile [1]. Orally administered DPP-4i increase
circulating concentrations of endogenous active GLP-1,
although to a lesser degree compared to GLP-1 ana-
logues [2] and lower glucose levels by stimulating insulin
secretion and inhibiting glucagon secretion.
In the recent consensus for the treatment of diabetes
[3] DPP-4i, such as vildagliptin and sitagliptin are rec-
ommended as second-line therapy in combination with
either metformin or sulfonylureas. In patients with dia-
betes type 2 who do not reach the glycemic targets with
metformin alone, DPP-4 inhibitors as add-on treatment
can efficiently lower glycosylated hemoglobin (HbA1c),
with neutral effects on body weight. Compared with sul-
fonylureas or thiazolidinediones, DPP-4 inhibitors exert
similar hypoglycemic efficacy and in addition are associ-
ated with a lower incidence of hypoglycemia or other
serious adverse events.
As first line therapy, DPP-4 inhibitors can be an alter-
native therapeutic option in patients who cannot tolerate
metformin because of gastrointestinal adverse events,
and several clinical studies have proved their efficacy as
monotherapy in drug-naïve patients with diabetes type
2. However, data are scarce regarding DPP-4 inhibitors
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as the first choice for diabetes management in everyday
clinical practice.
To address this issue we conducted a clinical study in
the outpatient setting using vildagliptin, which is a po-
tent and selective DPP-4i, as the first line treatment in
drug –naïve patients with newly diagnosed diabetes
type 2.
Methods
This was a 12-month clinical study that was conducted
in the outpatient setting of the Diabetes center of the
Endocrinology Division. All patients with newly diag-
nosed diabetes type 2 according to WHO criteria that
visited the outpatient clinic were initially screened for
eligibility. Exclusion criteria were secondary diabetes,
prior treatment with oral hypoglycemic agents or insu-
lin, malignancy, acute diabetic complications, myocardial
infarction, unstable angina, or coronary artery bypass
surgery within the previous 6 months, congestive heart
failure, NYHA Class III or IV, liver disease and renal in-
sufficiency (CrCl < 45 ml/min).
All participants provided written informed consent.
The protocol was approved by the ethics committee of
AHEPA University Hospital and the study was con-
ducted in accordance with the Declaration of Helsinki.
Study design
Eligible patients were initially left with lifestyle modification
instructions (diet and exercise) for 1–3 months without any
other particular treatment. Patients that failed to achieve
acceptable glucose levels (ie. FBG < 1120 and PBG < 200)
after this period were finally enrolled and scheduled on
regular visits every 4 months for one year. At visit 1 all pa-
tients received monotherapy with vildagliptin (50 mg twice
daily) for 4 months. At the end of the fourth month period
(visit 2), subjects that were not adequately controlled ac-
cording to their HbA1c (<7.0 %), received add-on therapy
with metformin (850 mg once daily). During the 3rd visit
(at the end of the 8th month) patients that did not reach
the target of HbA1c <7.0 % with metformin plus vildaglip-
tin received add-on therapy with a sulfonylurea (Glimepir-
ide 2 or 3 mg twice daily) (Fig. 1). All patients received a
BMI adjusted diabetic diet designed by a specialized diet-
ician of the diabetes center in the outpatient clinic that in-
cluded 50–55 % of carbohydrates, 30 % fat and 15–20 % f
proteins. The calculation of the daily kcals was performed
by a relevant application (Bmapp, iOS Developer program,
USA) that uses the BMI and the age of the patient and cal-
culates the ideal weight. Adjustments at each visit were
based on changes of the body weight of the patient. Pa-
tients who in visit 1 had triglycerides levels above 200 mg/
dl and/or total cholesterol > 240 mg/dl started treatment
with atorvastatin 20 mg.
According to the treatment applied during the study
patients were classified into 3 groups. Group 1: Received
vildagliptin for the whole study period (12 months).
Group 2. Received vildagliptin for 4 and vildagliptin plus
metformin for the remainder 8 months, Group 3: Re-
ceived vildagliptin for 4 months, vildagliptin plus metfor-
min for 4 months, and vildagliptin plus metformin plus
Fig. 1 Flow chart of the study design. Ninety one patients were enrolled in the study. After 4 months of vildagliptin monotherapy 36 patients reach the
target of HbA1c≤ 7.0 % and continue on vildagliptin treatment, while 55 patients needed add-on treatment with metformin. At the end of the 8th
month of treatment and according to HbA1c levels 27 patients needed triple therapy with glimepiride, 32 patients were on vildagliptin and metformin
and 32 patients continue on vildagliptn monotherapy
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sulfonylurea for the remainder 4 months (Fig. 1). Glyco-
sylated hemoglobin, fasting (FBG) and postprandial
blood glucose (PBG), body weight, fasting lipid profiles
(triglycerides; TG, total cholesterol; TC, LDL, HDL)
standard hematology and biochemistry laboratory as-
sessments and vital signs were measured at each study
visit. The PBG at each visit was self-assessed the previ-
ous day 2 h after their regular meal by the glucose-meter
provided by the outpatient clinic.
Blood pressure (BP) measurements were performed at
each study visit in the morning with the subjects in the
seated position following a 5 min quiet resting period.
Blood pressure was measured in both arms with a mer-
cury sphygmomanometer using an appropriately sized
cuff. Values for systolic BP (SBP) and diastolic BP (DBP)
were defined by Korotkoff phase I and IV respectively.
All patients were provided with glucose monitoring
devices and supplies and instructed on their use dur-
ing their first visit. Hypoglycemia was defined as self-
monitored blood glucose below 50 mg/dl with or
without symptomatology suggestive of low blood glu-
cose. Adverse events (AEs) were recorded at each
study visit and were assessed as to severity using the
criteria used by the ICH Guideline for Clinical Safety
Data Management (http://www.ema.europa.eu). If an
adverse event results in death is life-threatening,- re-
quires inpatient hospitalization or prolongation of exist-
ing hospitalization, − results in persistent or significant
disability/incapacity, or leads to discontinuation of the
treatment is categorized as severe. Classification of mild
or moderate adverse events and potential relationship
to the anti-diabetic treatment were based on the physi-
cians’ opinion taken into consideration the duration of
the event and the patient’s report.
Assays
All laboratory assessments were made using standard
techniques in the Central Laboratory of AHEPA Univer-
sity hospital. HbA1c was measured with an ion exchange
HPLC method.
Statistical analysis
The primary outcome was change from baseline in
HbA1c. Secondary outcomes included fasting and post-
prandial glucose levels, fasting plasma lipids, and body
weight. All values are presented as mean ± standard de-
viation (SD), or standard error of the mean (SE) when
stated. We used analysis of covariance (ANCOVA) to
test whether baseline values of HbA1c were significant
in determining the change of HbA1c (Δ HbA1c), after
administration of vildagliptin.
Changes from baseline in primary and secondary
endpoints were analyzed using an analysis of variance
(ANOVA). Pearson correlation coefficient (r) was
used to test the relationships between mean changes
of glucose parameters after treatment. The trapezoidal
rule was used to determine the area under the curve
(AUC).
We also used repeated measures analysis to determine
whether treatment with vildagliptin was effective over time.
Linear regression analysis was performed to create an algo-
rithm that quantifies the net effect of vildagliptin therapy
at various values of baseline HbA1c. A P value < 0.05 was
considered statistically significant. Data were analyzed
using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Ninety-one patients aged between 39 and 84 years old
(mean age 68 years) were finally enrolled in the study.
Anthropometric characteristics and baseline laboratory
values are summarized in (Table 1). Concomitant dis-
eases included arterial hypertension (n = 15), thyroid dis-
ease (n = 48), osteoporosis and other metabolic bone
diseases (n = 13), hypogonadism (n = 6) and hyperlipid-
emia (n = 2). Patients with previously diagnosed hyperlip-
idemia were on treatment with atorvastatin 20 mg/day for
approximately 2 years (n = 2) or rosumvastatin 5 mg/day
for 3,5 year (n = 1) and during laboratory examinations
their lipid profile was within normal values. However, at
visit one 31 patients had triglycerides >200 mg/dl and 25
of them had also total cholesterol >240 mg/dl. We pre-
scribed atorvastatin 20 mg/d in these patients. Concomi-
tant medications (including statins) remained unchanged
during the study period. Family history of diabetes was
positive in 71 % of the patient population. Blood pressure
measurements were within normal values during the
study period.
Table 1 Baseline and anthropometric characteristics of the
study population
N 91
Age (yrs) 68.4 ± 11.3
Μen (%) 55 (60 %)
BMI (kg/cm2) 28 ± 5.7
Obese patients (n,%) 28,30 %
Fasting blood glucose (mmol/l) 10.3 ± 2.4
HbA1c (%) 8.16 ± 1.6
Postprandial blood glucose (mmol/l) 11.7 ± 3.4
Urea (mmol/l) 10.67 ± 2.7
Creatinine (umol/l) 79.56 ± 26.52
Total Cholesterol (mmol/l) 5.7 ± 1
HDL (mmol/l) 1.15 ± 0.3
LDL (mmol/l) 3.6 ± 1.0
Triglycerides (mmol/l) 2.17 ± 1.0
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4 months monotherapy with vildagliptin
Glycosylated hemoglobin was significantly decreased
after 4 months monotherapy with vildagliptin from
8.16 % ± 1.60 at baseline to 7.52 % ± 1.60, p < 0.001. The
mean change of HbA1c was −0.6 and 39 % of the pa-
tients (n = 36) achieved the target of HbA1c ≤ 7.0 % at
the end of the 4th month. Similarly, significant reduc-
tions were observed in FBG, PBG and serum triglycer-
ides level (FBG: 185.5 ± 43.2 mg/dl vs. 135 ± 23.4 mg/dl,
p < 0.001, PBG: 210.8 ± 61.2 mg/dl vs. 165.7 ± 28.8 mg/dl
p < 0.001, TG: 186 ± 88.5 vs. 141.7 ± 62 mg/dl, p < 0.001).
Total cholesterol levels were also reduced, albeit not sig-
nificantly, after 4 months of treatment with vildagliptin
(220.4 ± 38.6 mg/dl vs. 208.8 ± 34.8 mg/dl p = 0.0719),
while there was no significant change in body weight.
Changes in HbA1c were unrelated to changes in FBG
and PBG levels.
Patients with baseline HbA1c values ≤ 8.0 % achieved
the target of HbA1c <7.0 % to a significantly greater per-
centage, compared to patients that had baseline values
above 8 % (46 % vs. 25 %, p < 0.001, respectively). Mean
change in HbA1c was significantly and inversely corre-
lated with baseline HbA1c values (r = −0.51, p < 0.001),
and this relationship remained robust after adjusting for
changes in body weight (ΔBMI), age, gender and base-
line FBG and PBG.
A linear regression analysis was used to create a statis-
tical model that quantifies the effect of HbA1C at base-
line on post-treatment HbA1c and concluded to the
following algorithm:
ΔHbA1c = 2, 40–0, 41 × HbA1cbaseline, which also
remained significant (R2 = 29,8 %, p < 0,001), after adjust-
ing for ΔBMI, age, gender and baseline FBG and PBG.
Mean change in fasting glucose levels (50.9 mg/dl) was
significantly and inversely correlated with baseline values of
fasting glucose (r = −0.848, p < 0.001). Mean change in post-
prandial glucose levels (37.9 mg/dl) was also significantly
correlated with baseline fasting (r = −0.269, p = 0.029) and
postprandial glucose levels (r = −0.882, p < 0.001). There
was no significant change in body weight.
12 month comparative study with vildagliptin
monotherapy versus combination therapy
During visits 2 and 3 patients either remained on vilda-
gliptin monotherapy (n = 32) or received add-on treat-
ment with metformin (n = 32) or received add-on
treatment with metformin and glimepiride (n = 27) ac-
cording to whether the HbA1c target of below 7.0 % was
achieved (Fig. 1).
Repeated measurements analysis for group 1 that re-
ceived vildagliptin monotherapy during the whole study
period, confirmed that there was no difference on the ef-
fect of vildagliptin overtime and that was true for both
males and females. There was no significant difference
between baseline values of fasting and postprandial glu-
cose and fasting lipids between the 3 groups, except for
HbA1c, as expected by study design (Table 2). Similarly
there were no significant between-groups differences in
mean changes in FBG and PBG (Table 3). However,
when we used AUC for the assessment of fluctuation of
HbA1c at the study intervals, AUC HBA1C 1–12 was sig-
nificantly higher in group 3 compared to groups 2 and 1
(6.27 ± 0.66 % vs. 5.54 ± 0.43 % vs. 4.7 ± 0.44, p < 0.001,
respectively). This was not the case when assessing AUC
for FBG (AUC FBG1–12) and PBG (AUC PBG1–12).
At the end of study period 90 % of the patients in the
vildagliptin monotherapy group, 56 % in the vildagliptin
plus metformin group and 44 % of the vildagliptin plus
metformin plus sulfonylurea group achieved the target
of HbA1c <7.0 %.
Table 2 Baseline values of diabetic patients treated with vildagliptin monotherapy versus ccombination treatment
Baseline values Group 1 (Vildagliptin) Group 2 (Vildagliptin +metformin) Group 3 (Vildagliptin+metformin +glimepiride) P
N 32 32 27 –
Age (yrs) 59.7 ± 10.2 63.1 ± 12.3 65 ± 10.5 0.23
Μen (%) 20 (62 %) 22 (68 %) 13 (48 %) –
BMI (kg/cm2) 28 ± 5 27 ± 4.6 29.6 ± 7.5 0.34
Fasting blood glucose (mmol/l) 10.5 ± 2.9 10.4 ± 2.1 9.7 ± 1.9 0.64
HbA1c (%) 7.4 ± 1.3 8.1 ± 1.6 9 ± 1.3 <0.001
Postprandial glucose (mmol/l) 11.2 ± 3.6 11.65 ± 2.9 12 ± 3.7 0.23
Total Cholesterol (mmol/l) 6.1 ± 0.9 5.6 ± 1.2 5.8 ± 0.8 0.46
HDL (mmol/l) 1.1 ± 0.2 1.2 ± 0.3 1.1 ± 0.3 0.30
LDL (mmol/l) 3.7 ± 0.9 3.3 ± 1.1 3.6 ± 0.8 0.41
Triglycerides (mmol/l) 1.9 ± 0.6 2.3 ± 1.3 2.3 ± 0.9 0.37
Systolic Blood pressure (mmHg) 120.9 ± 8.3 118.9 ± 7.2 121 ± 8.4 0.33
Diastolic Blood pressure (mmHg) 80.6 ± 7.3 79.9 ± 6.8 89.6 ± 7.3 0.47
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Mean changes of the parameters tested at the end of the
study
Mean changes in glucose levels, HbA1c, lipids and
weight are shown in Table 3. The mean change ± SE in
HbA1c from baseline to end point was larger in group 3
(−1.4 ± 0.25 %), compared to group 2 (−1.2 ± 0.27 %) and
group 1 (−0.9 ± 0.22 %), albeit not significantly (Table 3).
There was a significant reduction in FBG and PBG at
the end of the study in all groups. Triglycerides and total
cholesterol levels were significantly reduced in group 1
and group 2 while significant changes were seen in HDL
and LDL levels in groups 1 and 3, respectively.
Adverse events
No confirmed symptomatic or asymptomatic hypoglycemia
was reported during the study period. Most of the AEs that
were reported were mild or moderate in severity, did not
lead to discontinuation of the anti-diabetic treatment and
included nausea (n = 12) and gastrointestinal discomfort
(n = 5). One patient in the vildagliptin monotherapy group
reported an oedema in the lower extremities, which was
resolved in the first month of treatment.
In addition no adverse reactions attributed to drug- in-
teractions were reported during the study period. No
major changes from baseline to endpoint were observed
for any of the routinely assessed hematological or bio-
chemical parameters.
Discussion
The efficacy and safety of vildagliptin as monotherapy have
been widely confirmed in a large body of clinical studies in
various populations with type 2 diabetes [4–8]. In our
study and in agreement with previous data, vildagliptin
monotherapy (100 mg daily) produced a clinically signifi-
cant decrease in HbA1c as a first-line treatment in drug-
naïve patients with type 2 diabetes. However, the reduction
of HbA1c observed was lower in the older age patients
probably due to the longer duration of diabetes in this
group and was also lower compared to randomized clin-
ical trials, probably due to the nature of our study design
that do not allow us a tight control on the patient’s diet
and compliance to study drugs, which were both self-
reported.
Moreover we have shown a favorable lipid profile in
all three groups of treatment with significant reductions
in serum triglycerides and LDL cholesterol and signifi-
cant increases in HDL in combination with atorvastatin.
A small number of patients, achieved the target of
7.0 % in the first 4 months of vildagliptine monotherapy
(36 %) but most of them (approximately 90 %) sustain
HbA1c <7.0 % at least for 1 year after the first diagnosis
of their diabetes, in line with previous results demon-
strating a sustained effect of vildagliptin over time [8].
At the end of study period 90 % of the patients in the
vildagliptin monotherapy group, 56 % in the vildagliptin
plus metformin group and 44 % of the vildagliptin plus
metformin plus sulfonylurea group achieved the target
of HbA1c <7.0 %. Based on the algorithm that was de-
veloped by data from our patients we found that the
main determinant of vildagliptin efficacy as monother-
apy in drug-naïve patients was, baseline HbA1c as it
has also been shown for vildagliptin plus metformin
[9]. In a recent study by Takeshita et al., when vilda-
gliptin was compared to liraglutide as a second line
treatment after sitagliptin baseline levels of docosa-
hexanoic acid but not eicosapentanoic acid demon-
strated a significant predictive value for vildagliptin-
mediated improvement in glycemic control independent
of its effects on insulin secretion and insulin sensitivity
[10]. Detailed lipid parameters were not measured in our
study. In addition, our patients were drug naïve when vil-
dagliptine was initiated and thus our results are not
directly comparable with the study by Takeshita et al. [10].
Vildagliptin was well tolerated either as monotherapy or
in combination with metformin or metformin and glime-
piride, and no episodes of hypoglycemia were observed.
Table 3 Mean changes in glucose and lipids before and after treatment for 12 months
Mean change of tested parameters Group 1 Group 2 Group 3
Μean ± SE Vildagliptin monotherapy Vildagliptin +Metformin Vildagliptin+ Metformin +Glimepiride
Mean change in HbA1C (%) 0.9 ± 0.22 % p < 0.001 1.2 ± 0.27 % p < 0.001 1.4 ± 0.25 % p < 0.001
Mean change FBG (mg/dl) 68.57 ± 8.5 mg/dl p < 0.001 55.17 ± 9.6 mg/dl p < 0.001 101 ± 14 mg/dl p < 0.001
Mean change PBG (mg/dl) −37.24 ± 10 mg/dl p < 0.005 56.4 ± 13 mg/dl p < 0.001 120.2 ± 24.2 p < 0.001
Mean change triglycerides (mg/dl) 24.7 ± 16 mg/dl p < 0.001 52 ± 21 mg/dl p = 0.01 71 ± 33 mg/dl p = 0.27
Mean change total cholesterol (mg/dl) 12 ± 2 mg/dl p = 0.32 13 ± 10 mg/dl p = 0.21 17 ± 9 mg/dl p = 0.06
Mean change HDL (mg/dl) a 6.47 ± 4 mg/dl p = 0.02 4 ± 3 mg/dl p = 36 10 ± 5 mg/dl p = 0.26
Mean change LDL (mg/dl) 20.4 ± 6 mg/dl p = 0.77 41 ± 18 mg/dl p = 0.93 50 ± 13 mg/dl p = 0.08
Mean change BW (kg) 0.2 0.2 ± 0.03 p = 0.32 1.2 ± 0.2 1.2 p = 0.4 1.3 ± 0.6 kg 1.3 p = 0.48
aHDL level was increased after treatment
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Currently, most type 2 diabetes patients begin and
continue with the gold standard treatment of metformin
[11]. When metformin is not tolerated due to gastro-
intestinal side effects, such as diarrhea and nausea [12]
or is contraindicated, as in congestive heart failure and
renal disease, alternative first line treatments include sul-
fonylureas, thiazolidinediones and DPP-4i. Compared to
the first two drug categories DPP-4i are equally efficacious
in lowering HbA1c and have a favorable safety profile with
low risk of hypoglycemia due to the incretin-based mech-
anism of action and neutral effect on body weight.
In studies comparing vildagliptin to metformin vilda-
gliptin has proven non-inferiority and was better toler-
ated with fewer gastrointestinal adverse events [13–15].
Clinically relevant efficacy of vildagliptin was also seen
compared to rosiglitazone [16–18]. Both drugs decreased
HbA1c to a similar extent at short term with vildagliptin
showing some weight benefit [16]. Extension of this study
[16] over 2-years in drug-naïve diabetic patients also dem-
onstrated statistically significant and sustained HbA1c re-
ductions for both drugs with rosiglitazone showing
greater durability in lowering HbA1c at the expense of sig-
nificant weight gain and less favorable plasma lipid profile
compared with vildagliptin [17].
Compared to gliclazide, vildagliptin produced similar
HbA1c reductions over 2-years monotherapy but non-
inferiority was not established [19] despite the benefits
of vildagliptin in weight and hypoglycemia. In patients
with low baseline values of HbA1c vildagliptin and glime-
piride as add on treatment to metformin demonstrated
similar efficacy in reducing HbA1c with markedly reduced
hypoglycemia risk and no weight gain in the vildagliptin
plus metformin treated group [20, 21].
Overall, monotherapy with vildagliptin or vildagliptin
plus metformin controlled adequately HbA1c levels in
73 % of drug-naïve patients with newly diagnosed dia-
betes after 12 months of treatment in line with previous
results [4, 9, 22–24]. Patients that needed add-on treat-
ment with sulfonylurea were those with more pro-
nounced postprandial hyperglycemia and mean baseline
values of HbA1c around 9 %. We did not find significant
differences between treatment groups from baseline to
end point in the glucose parameters tested, probably due
to the small sample size in each group.
Conclusions
In summary we have shown that monotherapy of vilda-
gliptin as first line treatment or in combination with met-
formin in the outpatient setting is an effective approach in
a considerable number of patients albeit with an increased
cost relative to more conventional alternatives. Additional
benefits such as low risk of hypoglycemia, neutral effect
on body weight and favorable lipid profile can be particu-
larly appreciable in selective patients with low baseline
HbA1c levels or in the elderly population, as has been re-
cently shown [25].
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